Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval

Contraception

Volumn 69, Issue 1, 2004, Pages 3-7

  Smit, Jennifer ^a   Botha, Julia ^b   McFadyen, Lynn ^b,c   Beksinska, Mags ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Depot medroxyprogesterone acetate; Medroxyprogesterone acetate serum concentrations; Progestagen only injectable contraception; South Africa

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ETHNIC GROUP; ETHNOLOGY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OVULATION;

EID: 0346024001     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.09.005     Document Type: Article

References (19)

1. Kirton K.T., Cornette J.C. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera®). Contraception. 10:1974;39-45.
2. Jeppsson S., Johansson E.D., Ljungberg O., Sjoberg N.O. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea. Acta Obstet Gynecol Scand. 56:1977;43-48.
3. Oritz A., Hiroi M., Stanczyk F.Z., Goebelsmann U., Mishell D.R. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. J Clin Endocrinol Metab. 44:1977;32-38.
4. Koetsawang S., Shrimanker K., Fotherby K. Blood levels of medroxyprogesterone acetate after multiple injections of Depo Provera or Cyclo Provera. Contraception. 20:1979;1-4.
5. Fotherby K., Koetsawang S., Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception. 22:1980;527-536.
6. Fotherby K., Saxena B.N., Shrimanker K., et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril. 34:1980;131-139.
7. Bassol S., Garza-Flores J., Cravioto M.C., et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril. 42:1984;216-222.
8. Shrimanker K., Saxena B.N., Fotherby K. Radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem. 9:1978;359-363.
9. Jeppsson S., Johansson E.D.B. Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-Provera. Contraception. 14:1976;461-469.
10. Mishell D.R. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 41:1996;381-390.
11. South Africa Demographic and Health Survey 1998. Preliminary report. 1999;Department of Health, Pretoria.
12. Beksinska M.E., Rees H.V., Smit J. Temporary discontinuation a compliance issue in injectable users . Contraception. 64:2001;309-313.
13. Smit J, Gray A, McFadyen L, Zuma K. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Services Research 2001;1. Available at: http://www.biomedcentral.com/1472-6963/1/4. Accessed May 28, 2002.
14. th ed., amended May 1999. London: World Health Organisation Collaborating Centre for Immunoassay, 1998. p. 31-45.
15. Fraser I.S., Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust. 1:1981;1-20.
16. Sang G. Regional population differences and population pharmacokinetics of steroidal contraceptives. Snow R., Hall P. Steroid contraceptives and women's response. Regional variability in side-effects and pharmacokinetics. 1994;219-237 Plenum Press, New York.
17. Fotherby K., Koetsawang S. Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception. 26:1982;51-58.
18. Garza-Flores J., Sang G., Hall P.E. Population and delivery systems variability in pharmacokinetics of long-acting injectable contraceptives . Snow R., Hall P. Steroid contraceptives and women's response. Regional variability in side-effects and pharmacokinetics. 1994;69-83 Plenum Press, New York.
19. Schwallie P.C. Experience with Depo-Provera as an injectable contraceptive. J Reprod Med. 13:1974;113-117.